ESMO Congress 2025
Review videos and news releases from Dana-Farber physician-scientists at the ESMO Congress 2025.
ESMO25 Breast Cancer Highlights
Harold Burstein, MD, PhD, and other breast cancer experts at Dana-Farber discuss important breast cancer research presented at ESMO 2025.
Medical Oncology
ESMO25 Breast Cancer Highlights: evERA and SERENA6
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the evERA and SERENA6 trials investigating oral selective estrogen receptor degraders (SERDs).
Institute Physician
Assistant Professor of Medicine, Harvard Medical School
Assistant Professor of Medicine, Harvard Medical School
ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05
Harold Burstein, MD, PhD, and Guilherme Nader Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials examining trastuzumab deruxtecan in HER2-positive breast cancer.
Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss OptiTROP-Breast02 and other trials investigating antibody-drug conjugates (ADCs).
ESMO25 Breast Cancer Highlights: ASCENT-03 and TROPION-Breast02
Harold Burstein, MD, PhD, and Ana Garrido- Castro, MD, discuss the ASCENT-03 and TROPION-Breast02 trials, investigating antibody-drug conjugates for triple-negative breast cancer.
Medical Oncology
Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the monarchE and NATALEE trials, investigating CDK4/6 inhibitors for high-risk, early stage, HR+ breast cancer.
ESMO25 Breast Cancer Highlight Recap
Harold Burstein, MD, PhD, summarizes important breakthroughs presented at ESMO 2025 for all sub-types and stages of breast cancer.
Medical Oncology
2025 ESMO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2025
Medical Oncology
2025 ESMO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ESMO 2025.
Medical Oncology
2025 ESMO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2025.
Medical Oncology
FLAURA2 Lung Cancer Study Presented by Pasi Jänne, MD, PhD
Dana-Farber Cancer Institute's Dr. Pasi Jänne details FLAURA2 which found first-line osimertinib + platinum pemetrexed chemotherapy improved overall survival vs. monotherapy in EGFR mutated non-small cell lung cancer, including poorer prognosis patients.
Medical Oncology
KIM-1 in Kidney Cancer Study Presented by Vincent Xu, MD
Dana-Farber Cancer Institute's D. Wenxin (Vincent) Xu shares research suggesting a blood test measuring levels of the KIM-1 biomarker could help assess the burden of disease in advanced kidney cancer and predict outcomes during first-line treatment.
Medical Oncology
ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.
Medical Oncology
Head and Neck Study Presented by Robert Haddad, MD
Dana-Farber's Dr. Robert Haddad says research shows the combination of a PD1 with anti-LAG3 +/- anti-TIM3 does not improve outcomes in metastatic disease, raising the question of whether to look at this combo earlier, in the neoadjuvant setting.
Medical Oncology
The Next Frontier of Antibody-Drug Conjugate Development - Dana-Farber's Paolo Tarantino, MD, discussed how to optimize the safety of antibody drug conjugates at a session during ESMO25.
Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.
News Releases
- Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
- Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer
- ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
- Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
Featured Speakers
- Dana-Farber Oral Abstract Presentation Schedule at ESMO Congress 2025
- Keynote Lecture: Catherine Wu, MD on Therapeutic cancer vaccines: Clinical perspectives. October 19, 2025
- ESMO Congress 2025 Posters and ePoster presentations and abstracts, featuring Dana-Farber physician-scientists
Follow us on social media
- X (formerly Twitter)
- @DanaFarber Cancer Institute - Information on our expert cancer care and advanced research
- @DanaFarberNews - Your source for Dana-Farber news
- Bluesky